3D Medicines, Inc. (1244) AI Stock Analysis

• Market Cap: HK$1.23B
• Dividend Yield: N/A
• Average Volume (3M): 393.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: -8.43%
• EPS Growth: 64.33%
• Country: HK
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 258,177,000
• 10 Day Avg. Volume: 535,000
• 30 Day Avg. Volume: 393,126
• PEG Ratio: 0.06
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 1.56
• P/FCF Ratio: -2.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: HK$5.50 ▼(-10.42% Downside)

The overall stock score is primarily influenced by financial performance challenges, including negative margins and reliance on external financing. Technical indicators suggest a bearish trend, but oversold conditions could lead to a rebound. Valuation metrics are weak due to ongoing losses and lack of dividends.

Positive Factors

Strong cash position

A strong cash and short-term investment base provides a durable runway for costly oncology R&D and clinical programs, reducing near-term refinancing pressure. This supports continued product development and strategic flexibility over the next several quarters.

Sustained revenue growth trend

Consistent top-line growth across multiple years indicates commercial traction for therapies and diagnostics, suggesting scalable demand. Sustained revenue expansion improves the probability of reaching operating leverage and eventual profitability if margins and costs are managed.

High gross profit margins

Elevated gross margins imply product-level pricing power and attractive unit economics for core therapies. If the firm can control SG&A and R&D spending or scale sales, high gross margins provide a structural path to durable profitability once operating efficiencies are realized.

Negative Factors

Negative operating and free cash flow

Persistently negative operating and free cash flow indicate the business cannot self-fund growth or clinical programs, increasing reliance on external capital. Over months this undermines financial flexibility and raises execution risk for long-duration drug development projects.

Persistent net losses

Ongoing net losses despite revenue gains point to structural cost or scale issues. Continued losses reduce retained earnings and can constrain reinvestment, requiring profitable inflection or material cost restructuring to achieve sustainable long-term financial health.

Reliance on external financing and past leverage

Dependence on external funding and historical negative equity/high leverage heighten refinancing and dilution risks. Over a multi-month horizon this can constrain strategic choices, increase financing costs, and pressure management to prioritize cash generation over longer-term R&D investments.

3D Medicines, Inc. Business Overview & Revenue Model

Company Description

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

How the Company Makes Money

3D Medicines, Inc. generates revenue primarily through the sale of its pharmaceutical products and therapies, which are marketed to healthcare providers and institutions. The company may also derive income from licensing agreements with other pharmaceutical companies, allowing them to use its proprietary technologies or compounds. Additionally, strategic partnerships with research institutions and collaboration agreements can contribute to its revenue by providing funding for ongoing clinical trials and development projects. Government grants and funding for innovative healthcare solutions may also play a role in supporting the company's financial growth.

3D Medicines, Inc. Financial Statement Overview

Summary

3D Medicines, Inc. is experiencing significant revenue growth but continues to face profitability challenges. Negative margins and reliance on external financing are concerning, despite improvements in the balance sheet.

Income Statement

The company shows significant revenue growth from 2020 to 2024, with a strong increase in total revenue. However, the net income remains negative, indicating persistent losses. Gross profit margin is high, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a strong cash position with substantial cash equivalents and short-term investments. However, the company has a negative equity position until 2022, which improved in later years. The debt-to-equity ratio is concerning due to high leverage in earlier years, but it has improved recently.

Cash Flow

Operating cash flow has been negative, showing challenges in generating cash from core operations. Free cash flow is consistently negative, reflecting high capital expenditures and operational challenges. Financing cash flow is positive, indicating reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	448.39M	445.65M	634.95M	567.39M	60.26M	0.00
Gross Profit	373.68M	371.74M	524.01M	525.18M	55.98M	0.00
EBITDA	-199.91M	-226.95M	-529.23M	-1.03B	-1.45B	-303.35M
Net Income	-168.50M	-182.66M	-524.70M	-1.02B	-1.43B	-635.38M
Balance Sheet
Total Assets	1.14B	1.22B	1.43B	1.33B	1.06B	496.22M
Cash, Cash Equivalents and Short-Term Investments	447.10M	840.98M	996.58M	942.03M	824.48M	414.26M
Total Debt	162.97M	237.62M	282.43M	175.70M	3.15B	1.67B
Total Liabilities	509.91M	512.54M	558.20M	436.65M	3.33B	1.77B
Stockholders Equity	716.15M	785.06M	936.74M	943.00M	-2.24B	-1.27B
Cash Flow
Free Cash Flow	-55.38M	-249.60M	-150.74M	-332.76M	-433.46M	-289.48M
Operating Cash Flow	-48.66M	-210.58M	-144.41M	-278.78M	-377.08M	-278.33M
Investing Cash Flow	-91.12M	17.95M	-187.58M	-242.11M	-98.87M	-20.48M
Financing Cash Flow	-100.33M	-33.92M	304.51M	408.41M	840.08M	607.39M

3D Medicines, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Negative. The current price of 6.14 is above the 20-day moving average (MA) of 5.31, above the 50-day MA of 5.11, and above the 200-day MA of 5.62, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 16.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1244.

3D Medicines, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	60 Neutral	HK$3.18B	392.38	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6998	48 Neutral	HK$5.02B	56.31	2.04%	―	1447.56%	―
2137	43 Neutral	HK$1.09B	-2.71	-14.48%	―	―	-41.48%
6628	43 Neutral	HK$1.05B	-3.36	-34.18%	―	-57.84%	24.58%
1244	41 Neutral	HK$1.23B	-6.40	-21.45%	―	-8.43%	64.33%
2126	41 Neutral	HK$1.01B	-1.48	-51.56%	―	2.45%	2.58%

3D Medicines, Inc. Corporate Events

3D Medicines Appoints Veteran Capital Markets Executive as New CFO

3D Medicines Inc. has announced a leadership change in its finance function, with long-serving chief financial officer Zhang Jing resigning and experienced capital markets professional Lu Xiaohao taking over the role, effective immediately. Lu brings nearly 18 years of experience in capital operations, financial management and investment banking across domestic and international markets, including roles at PwC, Deloitte, GSK’s Greater China division, major Chinese securities firms and CFO positions at Wuhan Vickor Medical Technology and Hunan Hengchang Pharmaceutical Group, a move that may strengthen the company’s financial governance and capital markets capabilities as it pursues its strategic objectives.

The most recent analyst rating on (HK:1244) stock is a Sell with a HK$4.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines’ Envafolimab NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA

3D Medicines Inc. announced that China’s National Medical Products Administration has accepted its new drug application for Envafolimab (KN035) in combination with the GEMOX regimen as a first-line treatment for unresectable or metastatic biliary tract cancer, supported by data from a Phase III randomized, multicenter trial in Chinese patients. The move, if ultimately approved, would expand Envafolimab’s use beyond its current indication in MSI-H/dMMR advanced solid tumors, strengthening 3D Medicines’ position in the immuno-oncology market and potentially broadening the commercial prospects of its partnerships with Alphamab and regional licensees, though regulatory success is not assured.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Wins Third Orphan-Drug Designation for Envafolimab in Gastric Cancers

3D Medicines has received orphan-drug designation for its PD-L1 inhibitor Envafolimab (KN035) for the treatment of gastric cancer and gastro-esophageal junction cancer, marking the third such designation for the product after biliary tract cancer and soft tissue sarcoma. The new status is supported by Phase II data in advanced gastric/gastro-esophageal junction adenocarcinoma, where Envafolimab combined with FOLFOX achieved a 60% objective response rate and 100% disease control with favorable safety, reinforcing the drug’s clinical profile and strengthening 3D Medicines’ positioning in the global immuno-oncology market as it continues to expand regional licensing and commercialization of this first-in-class subcutaneous PD-L1 inhibitor.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.